» Articles » PMID: 38986621

Chimeric Antigen Receptor-induced Antigen Loss Protects CD5.CART Cells from Fratricide Without Compromising On-target Cytotoxicity

Abstract

Chimeric antigen receptor T cells (CART) targeting lymphocyte antigens can induce T cell fratricide and require additional engineering to mitigate self-damage. We demonstrate that the expression of a chimeric antigen receptor (CAR) targeting CD5, a prominent pan-T cell antigen, induces rapid internalization and complete loss of the CD5 protein on T cells, protecting them from self-targeting. Notably, exposure of healthy and malignant T cells to CD5.CART cells induces similar internalization of CD5 on target cells, transiently shielding them from cytotoxicity. However, this protection is short-lived, as sustained activity of CD5.CART cells in patients with T cell malignancies results in full ablation of CD5 T cells while sparing healthy T cells naturally lacking CD5. These results indicate that continuous downmodulation of the target antigen in CD5.CART cells produces effective fratricide resistance without undermining their on-target cytotoxicity.

Citing Articles

CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure?.

Maciocia N, Maciocia N, Wade B, Wade B, Maciocia P, Maciocia P Blood Adv. 2024; 9(4):913-923.

PMID: 39715467 PMC: 11876835. DOI: 10.1182/bloodadvances.2023012263.


Trogocytosis in CAR immune cell therapy: a key mechanism of tumor immune escape.

Chen Y, Xin Q, Zhu M, Qiu J, Qiu J, Li R Cell Commun Signal. 2024; 22(1):521.

PMID: 39468646 PMC: 11514842. DOI: 10.1186/s12964-024-01894-2.


Revolutionizing Cancer Treatments through Stem Cell-Derived CAR T Cells for Immunotherapy: Opening New Horizons for the Future of Oncology.

Mishra H, Kalyuzhny A Cells. 2024; 13(18.

PMID: 39329700 PMC: 11430090. DOI: 10.3390/cells13181516.

References
1.
Glisovic-Aplenc T, Diorio C, Chukinas J, Veliz K, Shestova O, Shen F . CD38 as a pan-hematologic target for chimeric antigen receptor T cells. Blood Adv. 2023; 7(16):4418-4430. PMC: 10440474. DOI: 10.1182/bloodadvances.2022007059. View

2.
Gomes-Silva D, Srinivasan M, Sharma S, Lee C, Wagner D, Davis T . CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017; 130(3):285-296. PMC: 5520470. DOI: 10.1182/blood-2017-01-761320. View

3.
Fry T, Shah N, Orentas R, Stetler-Stevenson M, Yuan C, Ramakrishna S . CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2017; 24(1):20-28. PMC: 5774642. DOI: 10.1038/nm.4441. View

4.
Klitgaard J, Koefoed K, Geisler C, Gadeberg O, Frank D, Petersen J . Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells. Br J Haematol. 2013; 163(2):182-93. DOI: 10.1111/bjh.12503. View

5.
Hill L, Rouce R, Wu M, Wang T, Ma R, Zhang H . Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas. Blood. 2023; 143(13):1231-1241. PMC: 10997912. DOI: 10.1182/blood.2023022204. View